NIDA Clinical Trials Network: New York Node

NIDA 临床试验网络：纽约节点

• 批准号: 10647100
• 负责人: Edward V. Nunes
• 金额: $ 70.82万
• 依托单位: NEW YORK UNIVERSITY SCHOOL OF MEDICINE
• 依托单位国家: 美国
• 财政年份: 2022
• 资助国家: 美国
• 起止时间: 2022-09-01 至 2023-02-28
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/10647100
• 关键词: Academia; Academic Medical Centers; Accident and Emergency department; Address; Adoption; Advocacy; Alaska Native; Alcohols; American Indians; Ancillary Study; Area; Attention; Behavior Therapy; Buprenorphine; Caring; Cities; Clinic; Clinical; Clinical Management; Clinical Trials; Clinical Trials Network; Collaborations; Communities; Criminal Justice; Data; Data Analytics; Data Science; Effectiveness; Electronic Health Record; Evidence based intervention; Funding; Future; Generations; Goals; Health; Health Personnel; Health system; Healthcare Systems; Helping to End Addiction Long-term; Individual; Infrastructure; Injections; International; Intervention; Lead; Leadership; Long Island; Longterm Follow-up; Mainstreaming; Medical; Mental Health; Mental disorders; Mentors; Mentorship; Minority; Mission; Naltrexone; National Institute of Drug Abuse; New York; Nicotine; Opioid; Patients; Pharmaceutical Preparations; Pharmacotherapy; Policies; Policy Maker; Prevention; Prevention trial; Primary Health Care; Provider; Public Health; Recording of previous events; Registries; Research; Research Personnel; Research Training; Schedule; Science; Scientist; Services; Structure; Surveys; Technology; Training; Training Programs; Translating; Treatment outcome; United States National Institutes of Health; Update; Vision; Withdrawal; Woman; Work; addiction; base; care providers; clinical care; clinical research site; cohort; cost effective; digital; digital intervention; digital treatment; health care settings; health data; health economics; implementation facilitation; implementation science; improved; innovation; interest; medical specialties; metropolitan; next generation; novel; opioid epidemic; opioid use; opioid use disorder; performance site; pre-exposure prophylaxis; precision medicine; predictive modeling; rural area; stimulant dependence; telehealth; therapy development; translational pipeline; treatment program; treatment research; treatment trial; virtual

The New York Node (NYN) of the NIDA CTN, led by John Rotrosen and Edward Nunes, represents the 2010 merger of the New York and Long Island Nodes, which had been part of the CTN since 2000 and 2001, respectively. This fourth competing renewal application builds on both a strong and successful infrastructure to manage clinical trials, and a track record of innovation and successful implementation of trials in mainstream healthcare settings where most SUD patients are seen. We contribute expertise in virtually all key CTN priorities outlined in RFA-DA-20-024, including: integration of SUD treatment and prevention in mainstream settings (primary care, emergency departments, criminal justice); leveraging the electronic health record to support improved and expanded care; developing medications and behavioral therapies; co-occurring medical and psychiatric disorders; women and minorities; digital and other technology-based interventions; data science including novel data analytic approaches; and implementation science, health economics, advocacy, and policy to sustain evidence-based interventions. In the new funding period, the NYN will lead or co-lead seven ambitious projects, all scheduled to begin in 2019 or 2020: CTN-0079-A1 Ancillary Study of the Adoption and Sustainability of ED-Initiated Buprenorphine; CTN-0082 Implementation Survey of PrEP and Opioid Use Related Services in STI Clinics and Community Based Organizations; CTN-0094 Individual Level Predictive Modeling of Opioid Use Disorder Treatment Outcome; CTN-0096 Culturally Centered MAT for OUD Implementation Facilitation for Primary Care and Addiction Treatment Programs Serving American Indian/Alaska Natives; CTN-0097 Surmounting Withdrawal to Initiate Fast Treatment with Naltrexone (SWIFT): Improving the Real-World Effectiveness of Injection Naltrexone for Opioid Use Disorder; CTN-0100 Optimizing Retention, Duration, and Discontinuation Strategies for Opioid Use Disorder Pharmacotherapy; and CTN-0101 Subthreshold Opioid Use Disorder Prevention (STOP) Trial. We will also continue to help develop new trials in CTN, including in the area of stimulant dependence, and to supply sites for CTN trials. To support this, we have built a network of collaborating researchers, providers, and policy makers from academia, community-based addiction treatment programs, large multifaceted healthcare systems, and NY City and State agencies, all in the nation’s largest and most diverse metropolitan area. We have established a track record of substantial contributions to the CTN, building on our work through deliberate, rigorous, and stepwise improvements. Our vision for the Network’s future includes work built around addressing gaps highlighted by the opioid treatment cascade, interventions for stimulant dependence, effective use of the CTN platform to enable a broad range of non-CTN studies, and a continued commitment to training a new generation of addictions clinical researchers. Further, we partner with implementation scientists, health economists, advocacy groups, and policy experts to maximize the sustainability of effective new interventions.

NIDA CTN 的纽约节点 (NYN) 由 John Rotrosen 和 Edward Nunes 领导，代表 2010 年 纽约节点和长岛节点的合并，这两个节点自 2000 年和 2001 年以来一直是 CTN 的一部分， 第四个竞争更新应用程序分别建立在强大且成功的基础设施之上。 管理临床试验，以及主流试验的创新和成功实施的记录 我们在几乎所有关键的 CTN 领域提供专业知识。 RFA-DA-20-024 中概述的优先事项，包括： 将 SUD 治疗和预防纳入主流 设置（初级保健、急诊科、刑事司法）；利用电子健康记录 支持改善和扩大护理；开发药物和行为疗法； 和精神疾病；数字和其他基于技术的干预措施； 科学，包括新颖的数据分析方法；以及实施科学、卫生经济学、宣传、 在新的资助期内，NYN 将领导或共同领导。 七个雄心勃勃的项目，全部计划于 2019 年或 2020 年开始：CTN-0079-A1 采用的辅助研究 ED 发起的丁丙诺啡的可持续性 CTN-0082 PrEP 和阿片类药物使用的实施调查 STI 诊所和社区组织的相关服务；CTN-0094 个人水平预测 阿片类药物使用障碍治疗结果建模；CTN-0096 以文化为中心的 OUD MAT 为美国人提供初级保健和成瘾治疗计划的实施便利 印第安/阿拉斯加原住民；CTN-0097 克服戒断症状，​​开始纳曲酮快速治疗 (SWIFT)： 提高注射纳曲酮治疗阿片类药物使用障碍的实际有效性；CTN-0100 优化； 阿片类药物使用障碍药物治疗的保留、持续时间和停药策略；和 CTN-0101 我们还将继续帮助开展新的阿片类药物使用障碍预防 (STOP) 试验。 CTN，包括兴奋剂依赖领域，并为 CTN 试验提供场地。 为了支持这一点，我们建立了一个由来自不同国家的研究人员、提供者和政策制定者组成的合作网络 学术界、基于社区的成瘾治疗计划、大型多方面医疗保健系统以及纽约 市和州机构均位于全国最大、最多元化的大都市区。 我们通过深思熟虑、严谨和严谨的工作，为 CTN 做出了重大贡献 我们对网络未来的愿景包括围绕解决差距开展工作。 以阿片类药物治疗级联、兴奋剂依赖干预措施、CTN 的有效使用为重点 平台，以实现广泛的非 CTN 研究，并持续致力于培训新的 此外，我们与实施科学家、健康专家合作。 经济学家、倡导团体和政策专家最大限度地提高有效新干预措施的可持续性。